Quality Tested Third-Party Verified Highly Purified U.S. Based Expert Support
PhysIQ PeptidesPhysIQ Peptides
Back to Shop
Tirzepatide 20mg research peptide vial

Tirzepatide

Tirzepatide (LY3298176)

Tirzepatide (LY3298176) is a 39-amino-acid synthetic peptide built on the native GIP sequence and engineered to activate both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). It contains two Aib residues for protease resistance and a lysine at position 20 acylated with a C20 fatty diacid through a γGlu-AEEA-AEEA linker, giving it an extended half-life through albumin binding.

Its discovery and preclinical pharmacology were described by Coskun and colleagues in Molecular Metabolism in 2018. Because it is "imbalanced", with GIP receptor potency comparable to native GIP and weaker potency at the GLP-1 receptor, it is a key reference compound for studying how dual incretin signaling differs from selective GLP-1 agonism.

Tirzepatide is the active ingredient in FDA-approved prescription drugs; this product is a research-grade material, not a drug product. PhysIQ Peptides supplies it as a lyophilized powder, third-party tested for purity and identity, for in vitro and laboratory research use only.

Select size

Choose how to buy

Your first order ships at the regular price. Every reship after that is 5% off. Pause, change the interval, or cancel anytime.

$135.00per vial · 20mg
Ask a Question
Third-party tested · Purity 99% · For laboratory research use only.
Purity
99%
Form
Powder (lyophilized)
CAS Number
2023788-19-2
Molecular Formula
C225H348N48O68
Molecular Weight
4813.45 g/mol
Available sizes
20mg, 40mg

Sequence

Y-Aib-EGTFTSDYSI-Aib-LDKIAQK(γGlu-2xAEEA-C20 diacid)AFVQWLIAGGPSSGAPPPS-NH2

Mechanism of Action

Tirzepatide binds and activates both GIPR and GLP-1R. In cell-based assays its affinity at the GIP receptor is similar to native GIP, while at the GLP-1 receptor it is several-fold weaker than native GLP-1 and shows biased signaling, favoring cAMP generation over β-arrestin recruitment. Researchers use it to study how combined incretin receptor activation affects insulin secretion and receptor internalization compared with single-receptor agonists.

Research Areas

  • ●Dual incretin receptor pharmacology (GIPR / GLP-1R)
  • ●Biased agonism and β-arrestin signaling
  • ●Beta-cell and insulin secretion models
  • ●Peptide acylation and half-life engineering

Selected References

  • Coskun T, et al. Mol Metab. 2018;18:3-14.

Related Products

VIP research peptide vial

VIP

Purity
≥99%
Size
10mg
Form
Powder
$60.00Per Unit
Vitamin B12 research peptide vial

Vitamin B12

Purity
≥99%
Size
10mg
Form
Powder
$48.00Per Unit
5-Amino-1MQ research peptide vial

5-Amino-1MQ

Purity
≥99%
Size
3 sizes
Form
Powder
From $35.00Per Unit
Adamax research peptide vial

Adamax

Purity
≥99%
Size
10mg
Form
Powder
$74.00Per Unit